Join our community of traders FOR FREE!

  • Learn
  • Improve yourself
  • Get Rewards
Learn More

The USD/SGD currency pair extended losses on Tuesday as US presidential election day put markets on edge.

According to Pepperstone’s Michael Brown, a victory for Donald Trump would likely prompt market players to focus on reflation, anticipated tax cuts and potential tariffs.

“Initial market reactions may include USD gains, especially against currencies at risk of tariffs, and Treasury downside, particularly at the long end of the curve as growth and inflation expectations rerate upward,” Brown said.

A victory for Kamala Harris could lead to weaker US Dollar, as Trump-linked hedges unwind.

An opinion poll over the weekend showed a surprise lead for Harris in Iowa, which is a traditional Republican stronghold. However, as a whole, polls continue to show a tight contest.

The Federal Reserve’s monetary policy decision will be another highlight this week.

The Fed is widely expected to cut its federal funds rate target range by 25 basis points to 4.50%-4.75% at its November meeting.

In September, the Fed began its monetary easing cycle with an out-sized rate cut (by 50 bps), which has been the first reduction in borrowing costs since March 2020.

The US central bank indicated confidence that inflation was moving sustainably toward the 2% target and took action to prevent a slowdown in the labor market.

Yet, the minutes of the latest FOMC meeting showed Fed officials were uncertain about the extent of interest rate cuts. Ultimately, only Governor Bowman voted against the 50 bps rate cut, while favoring a 25 bps move.

Meanwhile, data out of Singapore showed retail sales had increased 2% year-on-year in September, picking up from a 0.7% YoY rise in August. It has been the strongest retail sales growth since May.

As of 8:37 GMT on Tuesday the USD/SGD currency pair was edging down 0.13% to trade at 1.3178.

The exotic Forex pair has eased from a 12-week high of 1.3264, which it registered on November 1st.

TradingPedia.com is a financial media specialized in providing daily news and education covering Forex, equities and commodities. Our academies for traders cover Forex, Price Action and Social Trading.

Related News

  • Apple stays highly optimistic on iPhone sales as earnings beat estimatesApple stays highly optimistic on iPhone sales as earnings beat estimates The more positive outlook comes despite an 11% drop in full-year net profits and after a year when Apple’s share price fell heavily after hitting an all-time high.The iPhone maker reported a 5% year-on-year decline in earnings to $8.26 per […]
  • USD/ZAR propels to a fresh 1 1/2-week highUSD/ZAR propels to a fresh 1 1/2-week high The USD/ZAR currency pair traded in proximity to a fresh 1 1/2-week high of 17.8761 on Monday, supported by easing trade tensions following the announcement of a US-EU tariff deal.The US and the EU reached a framework trade agreement over […]
  • Mizuho Lifts Broadcom Price Target on Surging AI Demand and Expanding BacklogMizuho Lifts Broadcom Price Target on Surging AI Demand and Expanding Backlog Key Moments Mizuho raised its price target on Broadcom Inc (NASDAQ:AVGO) to $450 from $410 while maintaining an “Outperform” rating. Broadcom guided January-quarter revenue to about $19.1 billion, with expected AI sales of […]
  • Forex Market: EUR/AUD daily forecastForex Market: EUR/AUD daily forecast During yesterday’s trading session EUR/AUD traded within the range of 1.4312-1.4446 and closed at 1.4344.At 6:45 GMT today EUR/AUD was losing 0.45% for the day to trade at 1.4268. The pair touched a daily low at 1.4260 at 1:40 GMT, […]
  • South Korea’s Sep consumer sentiment at 4-month lowSouth Korea’s Sep consumer sentiment at 4-month low Consumer morale in South Korea has decreased to its lowest level since May in September, data by the Bank of Korea showed.The Composite Consumer Sentiment Index came in at a reading of 100.0 in September, down from 100.8 in […]
  • Chromocell Therapeutics amends stock repurchase planChromocell Therapeutics amends stock repurchase plan Chromocell Therapeutics Corporation (NYSE: CHRO) said on Thursday that its Board of Directors had authorized an amendment to the company’s existing stock repurchase plan.Under the amendment, the total value of shares of common stock […]